Results 11 to 20 of about 38,022 (310)

Adverse Effects of GLP-1 Receptor Agonists [PDF]

The Review of Diabetic Studies, 2014
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos, Thalia V, Panagiotopoulou, Moses S, Elisaf   +2 more
openaire   +2 more sources

Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Gαq pathway [PDF]

, 2015
The glucagon like peptide-1 receptor (GLP-1R) is a G-protein coupled receptor (GPCR) and an important target in the treatment of type 2 diabetes mellitus (T2DM).
Aiysha Thompson, Beinborn, Bhaskaran, Bhattacharyya, Bos, Budd, Budd, Cabrera-Vera, Chini, Cobb, Coopman, Crespo, Daaka, Davies, Davies, Davies, Della Rocca, Doyle, Eisinger, Gallwitz, Gedulin, Gurevich, Gutkind, Hanyaloglu, Hawes, Holst, Holst, Holz, Holz, Huang, Hunter, Irwin, Jolivalt, Kanamarlapudi, Kanamarlapudi, Kim, Knudsen, Koole, Kramer, Kuna, Le, Lee, Lopez-Ilasaca, Luttrell, Luttrell, Marchese, Martiny-Baron, McArdle, Montrose-Rafizadeh, Mundell, Nash, Quoyer, Rominger, Sloop, Soltoff, Syme, Tapia, Thompson, Tokuyama, Venkatakrishnan, Venkateswarlu Kanamarlapudi, Violin, Ward, Watanabe, Werry, Widmann, Widmann, Williams, Wootten, Wylie, Xiang, Zou   +71 more
core   +1 more source

Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor

Molecules, 2016
The glucagon-like peptide-1 receptor (GLP-1R) is an important target in the treatment of type 2 diabetes mellitus. The aim of this study was to compare the rate of agonist stimulated desensitization and internalization of GLP-1R.
Ghina Shaaban, Mabayoje Oriowo, Suleiman Al-Sabah   +2 more
doaj   +1 more source

Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. [PDF]

PLoS ONE, 2010
GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2168 h. Intraperitoneal glucose tolerance test (IPGTT) in mice showed that GLP-1/hIgG2 significantly decreased ...
Qinghua Wang, Kui Chen, Rui Liu, Fang Zhao, Sandeep Gupta, Nina Zhang, Gerald J Prud'homme   +6 more
doaj   +1 more source

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier, Cohen, Ohad, FILETTI, SEBASTIANO, Glandt, Mariela, MARANGHI, MARIANNA   +4 more
core   +2 more sources

The Cardiovascular Effects of GLP‐1 Receptor Agonists [PDF]

Cardiovascular Therapeutics, 2010
SUMMARYGlucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety.
Okerson, Theodore, Chilton, Robert J
openaire   +2 more sources

GLP-1 receptor agonist ameliorates experimental lung fibrosis [PDF]

Scientific Reports, 2020
AbstractIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease. This disease is characterized by an excessive accumulation of extracellular matrix deposition that modify normal lung physiology. Up to date, there are not efficient therapeutic tools to fight IPF. Glucagon-like peptide-1 receptor (GLP-1R) activation plays an
Juan Fandiño, Laura Toba, Lucas C. González-Matías, Yolanda Diz-Chaves, Federico Mallo   +4 more
openaire   +4 more sources

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst, Al-Sabah, Baggio, Beinborn, Biasini, Chen, Chen, Cheng, Coopman, Dan Donnelly, DeFronzo, Di Paolo, Donnelly, Drucker, Hoang, Hollenstein, Inooka, Kieffer, Knudsen, Koole, Koole, Koole, López de Maturana, López de Maturana, Mann, Mann, Mayo, Miller, Monaghan, Moon, Parthier, Perret, Pioszak, Rachel L. Dods, Roberts, Rodrigues, Runge, Runge, Sanchez, Siu, Solano, Tibaduiza, Turton, Underwood, Vertongen, Vilardaga, Wettergren, Wootten, Xiao, Yang, Ørskov   +50 more
core   +1 more source

GLP-1 receptor agonists for Parkinson's disease

Cochrane Database of Systematic Reviews, 2020
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney, Gonçalo S, Duarte, Joel, Handley, David Jw, Evans, Suresh, Menon, Richard, Wyse, Hedley Ca, Emsley   +6 more
openaire   +3 more sources

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad, Bell, Lauren N., Chalasani, Naga, Dineen, Stacey L., Fullenkamp, Allison M., McKenney, Mikaela L., Schultz, Kyle A., Sturek, Michael   +7 more
core   +1 more source